Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity.

Humans COVID-19 / immunology SARS-CoV-2 / immunology Antibodies, Viral / immunology Signal Transduction / immunology Interferons / metabolism Female Male Middle Aged Immunoglobulin G / blood CD4-Positive T-Lymphocytes / immunology Aged Adult Spike Glycoprotein, Coronavirus / immunology

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
16 May 2024
Historique:
received: 01 06 2023
accepted: 06 05 2024
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 16 5 2024
Statut: epublish

Résumé

Plasma RNAemia, delayed antibody responses and inflammation predict COVID-19 outcomes, but the mechanisms underlying these immunovirological patterns are poorly understood. We profile 782 longitudinal plasma samples from 318 hospitalized patients with COVID-19. Integrated analysis using k-means reveals four patient clusters in a discovery cohort: mechanically ventilated critically-ill cases are subdivided into good prognosis and high-fatality clusters (reproduced in a validation cohort), while non-critical survivors segregate into high and low early antibody responders. Only the high-fatality cluster is enriched for transcriptomic signatures associated with COVID-19 severity, and each cluster has distinct RBD-specific antibody elicitation kinetics. Both critical and non-critical clusters with delayed antibody responses exhibit sustained IFN signatures, which negatively correlate with contemporaneous RBD-specific IgG levels and absolute SARS-CoV-2-specific B and CD4

Identifiants

DOI: 10.1038/s41467-024-48556-y PMID: 38755196
pubmed: 38755196
doi: 10.1038/s41467-024-48556-y
pii: 10.1038/s41467-024-48556-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4177

Subventions

Organisme : amfAR, The Foundation for AIDS Research (amfAR)
ID : 110068-68-RGCV
Organisme : Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre)
ID : VR2-173203
Organisme : Canada Foundation for Innovation (Fondation canadienne pour l'innovation)
ID : 37521
Organisme : Canada Foundation for Innovation (Fondation canadienne pour l'innovation)
ID : 41027

Informations de copyright

© 2024. The Author(s).

Références

Brunet-Ratnasingham, E. et al. Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. Sci. Adv. 7, eabj5629 (2021).
pubmed: 34826237 pmcid: 8626074 doi: 10.1126/sciadv.abj5629
Pujadas, E. et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir. Med. 8, e70 (2020).
pubmed: 32771081 pmcid: 7836878 doi: 10.1016/S2213-2600(20)30354-4
Jarhult, J. D., Hultstrom, M., Bergqvist, A., Frithiof, R. & Lipcsey, M. The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID-19 patients. Sci. Rep. 11, 7163 (2021).
pubmed: 33785784 pmcid: 8010103 doi: 10.1038/s41598-021-86500-y
R. C. Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 400, 359–368 (2022).
doi: 10.1016/S0140-6736(22)01109-6
Rovito, R. et al. Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients. Sci. Rep. 12, 19658 (2022).
pubmed: 36385627 pmcid: 9667450 doi: 10.1038/s41598-022-23923-1
Bulow Anderberg, S. et al. Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine 138, 155389 (2021).
pubmed: 33348065 doi: 10.1016/j.cyto.2020.155389
Laing, A. G. et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 26, 1623–1635 (2020).
pubmed: 32807934 doi: 10.1038/s41591-020-1038-6
Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463–469 (2020).
pubmed: 32717743 pmcid: 7477538 doi: 10.1038/s41586-020-2588-y
R. C. Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637–1645 (2021).
doi: 10.1016/S0140-6736(21)00676-0
Investigators, R.-C. et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N. Engl. J. Med. 384, 1491–1502 (2021).
doi: 10.1056/NEJMoa2100433
Group, R. C. et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693–704 (2021).
doi: 10.1056/NEJMoa2021436
Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).
pubmed: 32972996 pmcid: 7857397 doi: 10.1126/science.abd4585
Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020).
pubmed: 32972995 pmcid: 7857407 doi: 10.1126/science.abd4570
Consortium, W. H. O. S. T. et al. Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results. N. Engl. J. Med. 384, 497–511 (2021).
doi: 10.1056/NEJMoa2023184
Kalil, A. C. et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 9, 1365–1376 (2021).
pubmed: 34672949 pmcid: 8523116 doi: 10.1016/S2213-2600(21)00384-2
Nienhold, R. et al. Two distinct immunopathological profiles in autopsy lungs of COVID-19. Nat. Commun. 11, 5086 (2020).
pubmed: 33033248 pmcid: 7546638 doi: 10.1038/s41467-020-18854-2
Asif, S. et al. Weak anti-SARS-CoV-2 antibody response is associated with mortality in a Swedish cohort of COVID-19 patients in critical care. Crit. Care 24, 639 (2020).
pubmed: 33158455 pmcid: 7645408 doi: 10.1186/s13054-020-03362-y
Zohar, T. et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell 183, 1508–1519.e1512 (2020).
pubmed: 33207184 pmcid: 7608014 doi: 10.1016/j.cell.2020.10.052
Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996–1012.e1019 (2020).
pubmed: 33010815 pmcid: 7494270 doi: 10.1016/j.cell.2020.09.038
Arunachalam, P. S. et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 369, 1210–1220 (2020).
pubmed: 32788292 pmcid: 7665312 doi: 10.1126/science.abc6261
Liu, C. et al. Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. Cell 184, 1836–1857.e1822 (2021).
pubmed: 33713619 pmcid: 7874909 doi: 10.1016/j.cell.2021.02.018
Moon, K. R. et al. Visualizing structure and transitions in high-dimensional biological data. Nat. Biotechnol. 37, 1482–1492 (2019).
pubmed: 31796933 pmcid: 7073148 doi: 10.1038/s41587-019-0336-3
Randolph, H. E. et al. Genetic ancestry effects on the response to viral infection are pervasive but cell type specific. Science 374, 1127–1133 (2021).
pubmed: 34822289 pmcid: 8957271 doi: 10.1126/science.abg0928
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102
Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091–1093 (2009).
pubmed: 19237447 pmcid: 2666812 doi: 10.1093/bioinformatics/btp101
Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369, eabc8511 (2020).
pubmed: 32669297 pmcid: 7402624 doi: 10.1126/science.abc8511
Brooks, D. G., Teyton, L., Oldstone, M. B. & McGavern, D. B. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J. Virol. 79, 10514–10527 (2005).
pubmed: 16051844 pmcid: 1182641 doi: 10.1128/JVI.79.16.10514-10527.2005
Teijaro, J. R. et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207–211 (2013).
pubmed: 23580529 pmcid: 3640797 doi: 10.1126/science.1235214
Nayrac, M. et al. Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. Cell Rep. 39, 111013 (2022).
pubmed: 35732172 pmcid: 9189142 doi: 10.1016/j.celrep.2022.111013
Fajnzylber, J. et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat. Commun. 11, 5493 (2020).
pubmed: 33127906 pmcid: 7603483 doi: 10.1038/s41467-020-19057-5
Gottlieb, R. L. et al. Early Remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med. 386, 305–315 (2022).
pubmed: 34937145 doi: 10.1056/NEJMoa2116846
Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N. Engl. J. Med. 385, e81 (2021).
pubmed: 34587383 doi: 10.1056/NEJMoa2108163
A.-T. L.-C. S. Group. et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N. Engl. J. Med. 384, 905–914 (2021).
doi: 10.1056/NEJMoa2033130
R. C. Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399, 665–676 (2022).
doi: 10.1016/S0140-6736(22)00163-5
Crotty, S. Follicular helper CD4 T cells (TFH). Annu Rev. Immunol. 29, 621–663 (2011).
pubmed: 21314428 doi: 10.1146/annurev-immunol-031210-101400
Major, J. et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science 369, 712–717 (2020).
pubmed: 32527928 pmcid: 7292500 doi: 10.1126/science.abc2061
Domizio, J. D. et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature 603, 145–151 (2022).
pubmed: 35045565 pmcid: 8891013 doi: 10.1038/s41586-022-04421-w
Palacio, N. et al. Early type I IFN blockade improves the efficacy of viral vaccines. J. Exp. Med. 217, e20191220 (2020).
pubmed: 32820330 pmcid: 7953731 doi: 10.1084/jem.20191220
Wilson, E. B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202–207 (2013).
pubmed: 23580528 pmcid: 3704950 doi: 10.1126/science.1235208
Hoang, T. N. et al. Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques. bioRxiv, https://doi.org/10.1101/2022.10.21.512606 (2022).
Papatriantafyllou, M. The interferon paradox. Nat. Rev. Immunol. 13, 392–393 (2013).
pubmed: 23648970 doi: 10.1038/nri3461
Sandler, N. G. et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601–605 (2014).
pubmed: 25043006 pmcid: 4418221 doi: 10.1038/nature13554
Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92–98 (2021).
pubmed: 33307546 doi: 10.1038/s41586-020-03065-y
Lee, J. S. et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci. Immunol. 5, eabd1554 (2020).
pubmed: 32651212 pmcid: 7402635 doi: 10.1126/sciimmunol.abd1554
Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045.e1039 (2020).
pubmed: 32416070 pmcid: 7227586 doi: 10.1016/j.cell.2020.04.026
Jhuti, D. et al. Interferon treatments for SARS-CoV-2: challenges and opportunities. Infect. Dis. Ther. 11, 953–972 (2022).
pubmed: 35445964 pmcid: 9022612 doi: 10.1007/s40121-022-00633-9
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
pubmed: 19910308 doi: 10.1093/bioinformatics/btp616
Prevost, J. et al. Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike. Cell Rep. Med. 1, 100126 (2020).
pubmed: 33015650 pmcid: 7524645 doi: 10.1016/j.xcrm.2020.100126
Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630–633 (2020).
pubmed: 32245784 pmcid: 7164391 doi: 10.1126/science.abb7269
Pearson, K. LIII. On lines and planes of closest fit to systems of points in space. Lond. Edinb. Dublin Philos. Mag. J. Sci. 2, 559–572 (1901).
doi: 10.1080/14786440109462720
Lloyd, S. P. Least squares quantization in PCM. IEEE Trans. Inf. Theory 28, 129–136 (1982).
doi: 10.1109/TIT.1982.1056489
Pedregosa, F. et al. Scikit-learn: machine learning in Python. J. Mach. Learn. Res. 12, 2825–2830 (2011).
Burkhardt, D. B. et al. Quantifying the effect of experimental perturbations at single-cell resolution. Nat. Biotechnol. 39, 619–629 (2021).
Saravanan, V., Berman, G. J. & Sober, S. J. Application of the hierarchical bootstrap to multi-level data in neuroscience. Neuron Behav. Data Anal. Theory 3, 1–25 (2020).
Efron, B. & Tibshirani, R. J. An Introduction to the Bootstrap. (CRC Press, 1994).
Ritz, C., Baty, F., Streibig, J. C. & Gerhard, D. Dose-response analysis using R. PLoS One 10, e0146021 (2015).
pubmed: 26717316 pmcid: 4696819 doi: 10.1371/journal.pone.0146021
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. Embnet. J. 17, 10–12 (2011).
doi: 10.14806/ej.17.1.200
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886 doi: 10.1093/bioinformatics/bts635
Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
pubmed: 24485249 pmcid: 4053721 doi: 10.1186/gb-2014-15-2-r29
Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 25605792 pmcid: 4402510 doi: 10.1093/nar/gkv007
Nedelec, Y. et al. Genetic ancestry and natural selection drive population differences in immune responses to pathogens. Cell 167, 657–669 e621 (2016).
pubmed: 27768889 doi: 10.1016/j.cell.2016.09.025
Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. Proc. Natl Acad. Sci. USA 100, 9440–9445 (2003).
pubmed: 12883005 pmcid: 170937 doi: 10.1073/pnas.1530509100
Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).
doi: 10.1186/1471-2105-14-7
Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021 pmcid: 4707969 doi: 10.1016/j.cels.2015.12.004

Auteurs

Elsa Brunet-Ratnasingham (E)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.
Department of Medicine, University of California, San Francisco, CA, USA.

Sacha Morin (S)

Department of Computer Science and Operations Research, Université de Montréal, Montreal, QC, Canada.
Mila-Quebec AI Institute, Montreal, QC, Canada.

Haley E Randolph (HE)

Committee on Genetics, Genomics, and Systems Biology, University of Chicago, Chicago, IL, USA.
ORCID: 0000-0003-2044-1180

Marjorie Labrecque (M)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Bioinformatics Program, Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, QC, Canada.

Justin Bélair (J)

Department of Mathematics and Statistics, Université de Montréal, Montreal, QC, Canada.
Independent Data Scientist, JB Consulting, Montreal, QC, H3S1K8, Canada.
ORCID: 0000-0002-4219-1824

Raphaël Lima-Barbosa (R)

Department of Mathematics and Statistics, Université de Montréal, Montreal, QC, Canada.
Independent Data Scientist, JB Consulting, Montreal, QC, H3S1K8, Canada.

Amélie Pagliuzza (A)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Lorie Marchitto (L)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.

Michael Hultström (M)

Anaesthesiology and Intensive Care Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. michael.hultstrom@mcb.uu.se.
Integrative Physiology, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden. michael.hultstrom@mcb.uu.se.
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada. michael.hultstrom@mcb.uu.se.
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada. michael.hultstrom@mcb.uu.se.
ORCID: 0000-0003-4675-1099

Julia Niessl (J)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.
BioNTech SE, Mainz, Germany.
ORCID: 0000-0001-8852-1924

Rose Cloutier (R)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Alina M Sreng Flores (AM)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Nathalie Brassard (N)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
ORCID: 0000-0002-4320-9416

Mehdi Benlarbi (M)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.

Jérémie Prévost (J)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.

Shilei Ding (S)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Sai Priya Anand (SP)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.

Gérémy Sannier (G)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.
ORCID: 0000-0001-7956-4463

Amanda Marks (A)

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0002-3961-8831

Dick Wågsäter (D)

Integrative Physiology, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.

Eric Bareke (E)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Hugo Zeberg (H)

Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Department of Evolutionary Genetics, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany.
ORCID: 0000-0001-7118-1249

Miklos Lipcsey (M)

Anaesthesiology and Intensive Care Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Hedenstierna Laboratory, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0002-1976-4129

Robert Frithiof (R)

Anaesthesiology and Intensive Care Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0003-2278-7951

Anders Larsson (A)

Clinical Chemistry, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0003-3161-0402

Sirui Zhou (S)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Human Genetics, McGill University, Montreal, QC, Canada.
ORCID: 0000-0003-4963-0815

Tomoko Nakanishi (T)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Human Genetics, McGill University, Montreal, QC, Canada.
Kyoto-McGill International Collaborative School in Genomic Medicine, Gaduate School of Medicine, Kyoto University, Kyoto, Japan.
Research Fellow, Japan Society for the Promotion of Science, Tokyo, Japan.
ORCID: 0000-0001-9510-5646

David Morrison (D)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
ORCID: 0000-0001-8380-3615

Dani Vezina (D)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.
ORCID: 0000-0002-0780-8593

Catherine Bourassa (C)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Gabrielle Gendron-Lepage (G)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Halima Medjahed (H)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Floriane Point (F)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Jonathan Richard (J)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Catherine Larochelle (C)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Department of Neurosciences, Université de Montréal, Montreal, QC, Canada.
ORCID: 0000-0002-8724-4782

Alexandre Prat (A)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Department of Neurosciences, Université de Montréal, Montreal, QC, Canada.
ORCID: 0000-0001-6188-0580

Janet L Cunningham (JL)

Department of Medical Sciences, Psychiatry, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0001-7876-7779

Nathalie Arbour (N)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Department of Neurosciences, Université de Montréal, Montreal, QC, Canada.
ORCID: 0000-0002-3718-1584

Madeleine Durand (M)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.

J Brent Richards (JB)

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Human Genetics, McGill University, Montreal, QC, Canada.
Department of Twin Research, King's College London, London, UK.
ORCID: 0000-0002-3746-9086

Kevin Moon (K)

Department of Mathematics and Statistics, Utah State University, Logan, UT, USA.

Nicolas Chomont (N)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.
ORCID: 0000-0001-9747-5018

Andrés Finzi (A)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.
Department of Microbiology and Immunology, McGill University, Montreal, QC, H3A 2B4, Canada.

Martine Tétreault (M)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Department of Neurosciences, Université de Montréal, Montreal, QC, Canada.

Luis Barreiro (L)

Committee on Genetics, Genomics, and Systems Biology, University of Chicago, Chicago, IL, USA.
Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, USA.
Committee on Immunology, University of Chicago, Chicago, IL, USA.
ORCID: 0000-0001-9456-367X

Guy Wolf (G)

Department of Computer Science and Operations Research, Université de Montréal, Montreal, QC, Canada. guy.wolf@umontreal.ca.
Mila-Quebec AI Institute, Montreal, QC, Canada. guy.wolf@umontreal.ca.
Department of Mathematics and Statistics, Université de Montréal, Montreal, QC, Canada. guy.wolf@umontreal.ca.
ORCID: 0000-0002-6740-059X

Daniel E Kaufmann (DE)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada. daniel.kaufmann@chuv.ch.
Département de Médecine, Université de Montréal, Montreal, QC, Canada. daniel.kaufmann@chuv.ch.
Division of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. daniel.kaufmann@chuv.ch.
ORCID: 0000-0003-4467-136X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Sustained IFN signaling is associated with...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Sustained IFN signaling is associated with...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Sustained IFN signaling is associated with...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Sustained IFN signaling is associated with...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Sustained IFN signaling is associated with...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Sustained IFN signaling is associated with...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Sustained IFN signaling is associated with...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline G › Sustained IFN signaling is associated with...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › Sustained IFN signaling is associated with...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sustained IFN signaling is associated with...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sustained IFN signaling is associated with...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › Glycoprotéine de spicule des coronavirus › Sustained IFN signaling is associated with...